Evidence map›Paper›PMID 29200599›Full record

ArticleDisease markers2017

Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma.

Anja Kafka, Davor Tomas, Mirna Lechpammer, Tea Gabud, Leo Pažanin, Nives Pećina-Šlaus

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Frontiers in molecular neuroscience · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Anja KafkaLaboratory of Neuro-oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 12, Zagreb, Croatia.ORCID 0000-0001-8457-5757
Davor TomasDepartment of Pathology, School of Medicine, University of Zagreb, Salata 10, 10000 Zagreb, Croatia.ORCID 0000-0003-3390-8683
Mirna LechpammerDepartment of Pathology & Laboratory Medicine, University of California, Davis Medical Center, 4400 V Street, Sacramento, CA 95817, USA.
Tea GabudLaboratory of Neuro-oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 12, Zagreb, Croatia.ORCID 0000-0002-4114-8365
Leo PažaninUniversity Hospital "Sisters of Charity", Vinogradska 29, 10000 Zagreb, Croatia.ORCID 0000-0002-4540-4055
Nives Pećina-ŠlausLaboratory of Neuro-oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 12, Zagreb, Croatia.ORCID 0000-0002-3334-7671
University of Zagreb · HRSisters of Charity Hospital · HRUniversity of California Davis Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression patterns of critical molecular components of Wnt signaling, sFRP3 and DVL3, were investigated in glioblastoma, the most aggressive form of primary brain tumors, with the aim to offer potential biomarkers. The protein expression levels and localizations in tumor tissue were revealed by immunohistochemistry and evaluated by the semiquantitative method and immunoreactivity score. Majority of glioblastomas had moderate expression levels for both DVL3 (52.4%) and sFRP3 (52.3%). Strong expression levels were observed in 23.1% and 36.0% of samples, respectively. DVL3 was localized in cytoplasm in 97% of glioblastomas, of which 44% coexpressed the protein in the nucleus. sFRP3 subcellular distribution showed that it was localized in the cytoplasm in 94% of cases. Colocalization in the cytoplasm and nucleus was observed in 50% of samples. Wilcox test indicated that the domination of the strong signal is in connection with simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expression of DVL3 will significantly more often have the protein in the nucleus (

Indexed as

Adaptor Proteins, Signal TransducingAdultAgedBiomarkers, TumorBrain NeoplasmsCell NucleusCytoplasmDishevelled ProteinsFemaleGlioblastomaHumansMaleMiddle AgedMuscle ProteinsProtein TransportAdaptor Proteins, Signal TransducingBiomarkers, TumorDishevelled ProteinsDVL3 protein, humanMuscle ProteinsMYOZ3 protein, human

Identifiers

PMID29200599
PMCPMC5671711
OpenAlexW2766175570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.